183 related articles for article (PubMed ID: 28643014)
1. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.
Davidson B; Hellesylt E; Holth A; Danielsen HE; Skeie-Jensen T; Katz B
Virchows Arch; 2017 Sep; 471(3):355-362. PubMed ID: 28643014
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.
Hwang H; Matsuo K; Duncan K; Pakzamir E; Pham HQ; Correa A; Fedenko A; Mhawech-Fauceglia P
J Clin Pathol; 2015 Sep; 68(9):710-7. PubMed ID: 25991737
[TBL] [Abstract][Full Text] [Related]
3. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China.
Li D; Yin N; Du G; Wang S; Xiao Z; Chen J; Chen W
Int J Biol Sci; 2020; 16(3):388-395. PubMed ID: 32015676
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Tumour Biol; 2011 Jun; 32(3):451-9. PubMed ID: 21161468
[TBL] [Abstract][Full Text] [Related]
6. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.
Davidson B; Abeler VM; Hellesylt E; Holth A; Shih IeM; Skeie-Jensen T; Chen L; Yang Y; Wang TL
Gynecol Oncol; 2013 Feb; 128(2):349-55. PubMed ID: 23178314
[TBL] [Abstract][Full Text] [Related]
7. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Cosio S; Tisi G; Lissoni A; Ferrero AM; Cristofani R
Eur J Gynaecol Oncol; 2002; 23(4):295-9. PubMed ID: 12214727
[TBL] [Abstract][Full Text] [Related]
8. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
Wang F; Dai X; Chen H; Hu X; Wang Y
BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
[TBL] [Abstract][Full Text] [Related]
11. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
12. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
[TBL] [Abstract][Full Text] [Related]
13. State of the science: Uterine sarcomas: From pathology to practice.
Shushkevich A; Thaker PH; Littell RD; Shah NA; Chiang S; Thornton K; Hensley ML; Slomovitz BM; Holcomb KM; Leitao MM; Toboni MD; Powell MA; Levine DA; Dowdy SC; Klopp A; Brown J
Gynecol Oncol; 2020 Oct; 159(1):3-7. PubMed ID: 32839026
[No Abstract] [Full Text] [Related]
14. Morcellating uterine mesenchymal tumors: The pathologist's view.
Pavlakis K; Messini I; Yiannou P; Gavresea T; Chrysanthakis D; Hilaris G; Panoskaltsis T
J Obstet Gynaecol Res; 2017 Mar; 43(3):580-586. PubMed ID: 28120430
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and outcome in women with uterine sarcoma.
Denschlag D; Masoud I; Stanimir G; Gilbert L
Eur J Surg Oncol; 2007 Feb; 33(1):91-5. PubMed ID: 17174517
[TBL] [Abstract][Full Text] [Related]
16. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases.
Kurihara S; Oda Y; Ohishi Y; Iwasa A; Takahira T; Kaneki E; Kobayashi H; Wake N; Tsuneyoshi M
Am J Surg Pathol; 2008 Aug; 32(8):1228-38. PubMed ID: 18580489
[TBL] [Abstract][Full Text] [Related]
17. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
[TBL] [Abstract][Full Text] [Related]
18. Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas.
Nielsen B; Hveem TS; Kildal W; Abeler VM; Kristensen GB; Albregtsen F; Danielsen HE
Cytometry A; 2015 Apr; 87(4):315-25. PubMed ID: 25483227
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment in adult uterine sarcomas.
Desar IME; Ottevanger PB; Benson C; van der Graaf WTA
Crit Rev Oncol Hematol; 2018 Feb; 122():10-20. PubMed ID: 29458779
[TBL] [Abstract][Full Text] [Related]
20. Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma.
Kubo T; Sugita S; Wada R; Kikuchi N; Iwasaki M; Ito Y; Sugawara T; Fujita H; Emori M; Tanaka R; Hirano H; Saito T; Hasegawa T
Diagn Pathol; 2017 Mar; 12(1):26. PubMed ID: 28288693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
